Denosumab increased significantly bone mass in all three dual X-ray absorptiometry standard sites, while alendronate did not at total hip.

No benefit was observed in men previously treated with alendronate who switched to denosumab treatment.

Autor: Planas Morin J, Celma Domenech A, Placer Santos J, Trilla Herrera E, Salvador Lacambra C,…

Leave a Reply

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

  • 3 × dos =